vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and La Rosa Holdings Corp. (LRHC). Click either name above to swap in a different company.

GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $20.2M, roughly 1.8× La Rosa Holdings Corp.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -27.4%, a 23.7% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 3.2%). Over the past eight quarters, La Rosa Holdings Corp.'s revenue compounded faster (72.5% CAGR vs 17.0%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

V. La Rosa and Sons Macaroni Company was founded in 1914 by Vincenzo La Rosa, a Sicilian immigrant. The company eventually became one of the largest regional brands in the United States producing over 40 varieties of pasta.

GYRE vs LRHC — Head-to-Head

Bigger by revenue
GYRE
GYRE
1.8× larger
GYRE
$37.2M
$20.2M
LRHC
Growing faster (revenue YoY)
GYRE
GYRE
+30.3% gap
GYRE
33.4%
3.2%
LRHC
Higher net margin
GYRE
GYRE
23.7% more per $
GYRE
-3.7%
-27.4%
LRHC
Faster 2-yr revenue CAGR
LRHC
LRHC
Annualised
LRHC
72.5%
17.0%
GYRE

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
GYRE
GYRE
LRHC
LRHC
Revenue
$37.2M
$20.2M
Net Profit
$-1.4M
$-5.5M
Gross Margin
95.3%
8.4%
Operating Margin
0.3%
-24.7%
Net Margin
-3.7%
-27.4%
Revenue YoY
33.4%
3.2%
Net Profit YoY
-340.1%
-125.7%
EPS (diluted)
$-0.01
$-5.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
LRHC
LRHC
Q4 25
$37.2M
Q3 25
$30.6M
$20.2M
Q2 25
$26.8M
$23.2M
Q1 25
$22.1M
$17.5M
Q4 24
$27.9M
$17.7M
Q3 24
$25.5M
$19.6M
Q2 24
$25.2M
$19.1M
Q1 24
$27.2M
$13.1M
Net Profit
GYRE
GYRE
LRHC
LRHC
Q4 25
$-1.4M
Q3 25
$5.9M
$-5.5M
Q2 25
$1.6M
$78.4M
Q1 25
$3.7M
$-95.7M
Q4 24
$569.0K
$-5.1M
Q3 24
$2.9M
$-2.5M
Q2 24
$4.5M
$-2.3M
Q1 24
$9.9M
$-4.6M
Gross Margin
GYRE
GYRE
LRHC
LRHC
Q4 25
95.3%
Q3 25
94.7%
8.4%
Q2 25
95.7%
8.0%
Q1 25
95.9%
8.8%
Q4 24
95.8%
8.9%
Q3 24
96.2%
8.3%
Q2 24
96.9%
8.3%
Q1 24
96.4%
8.9%
Operating Margin
GYRE
GYRE
LRHC
LRHC
Q4 25
0.3%
Q3 25
22.7%
-24.7%
Q2 25
8.1%
-10.6%
Q1 25
10.3%
-26.7%
Q4 24
2.4%
-17.1%
Q3 24
16.6%
-8.9%
Q2 24
12.7%
-9.7%
Q1 24
29.7%
-35.0%
Net Margin
GYRE
GYRE
LRHC
LRHC
Q4 25
-3.7%
Q3 25
19.4%
-27.4%
Q2 25
5.9%
337.8%
Q1 25
16.9%
-546.5%
Q4 24
2.0%
-28.7%
Q3 24
11.2%
-12.5%
Q2 24
18.0%
-12.2%
Q1 24
36.6%
-35.1%
EPS (diluted)
GYRE
GYRE
LRHC
LRHC
Q4 25
$-0.01
Q3 25
$0.03
$-5.44
Q2 25
$0.00
$15.25
Q1 25
$0.00
$-5.86
Q4 24
$0.00
$28.54
Q3 24
$0.01
$-16.49
Q2 24
$0.01
$-12.49
Q1 24
$0.03
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
LRHC
LRHC
Cash + ST InvestmentsLiquidity on hand
$52.4M
$4.0M
Total DebtLower is stronger
$642.8K
Stockholders' EquityBook value
$106.0M
$1.6M
Total Assets
$166.1M
$21.7M
Debt / EquityLower = less leverage
0.41×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
LRHC
LRHC
Q4 25
$52.4M
Q3 25
$60.0M
$4.0M
Q2 25
$54.4M
$5.1M
Q1 25
$29.9M
$2.9M
Q4 24
$26.7M
$1.4M
Q3 24
$25.1M
$1.8M
Q2 24
$25.1M
$1.6M
Q1 24
$37.4M
$1.1M
Total Debt
GYRE
GYRE
LRHC
LRHC
Q4 25
Q3 25
$642.8K
Q2 25
$644.3K
Q1 25
$645.9K
Q4 24
$647.6K
Q3 24
$649.2K
Q2 24
$650.8K
Q1 24
$652.4K
Stockholders' Equity
GYRE
GYRE
LRHC
LRHC
Q4 25
$106.0M
Q3 25
$101.9M
$1.6M
Q2 25
$92.0M
$3.4M
Q1 25
$68.1M
$-87.5M
Q4 24
$63.3M
$2.6M
Q3 24
$63.2M
$5.0M
Q2 24
$60.4M
$4.7M
Q1 24
$56.6M
$5.6M
Total Assets
GYRE
GYRE
LRHC
LRHC
Q4 25
$166.1M
Q3 25
$159.4M
$21.7M
Q2 25
$152.6M
$22.9M
Q1 25
$129.8M
$21.0M
Q4 24
$125.4M
$19.4M
Q3 24
$125.2M
$19.7M
Q2 24
$120.9M
$18.7M
Q1 24
$122.0M
$16.3M
Debt / Equity
GYRE
GYRE
LRHC
LRHC
Q4 25
Q3 25
0.41×
Q2 25
0.19×
Q1 25
Q4 24
0.25×
Q3 24
0.13×
Q2 24
0.14×
Q1 24
0.12×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
LRHC
LRHC
Operating Cash FlowLast quarter
$-5.6M
$-1.3M
Free Cash FlowOCF − Capex
$-5.8M
FCF MarginFCF / Revenue
-15.5%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
LRHC
LRHC
Q4 25
$-5.6M
Q3 25
$4.7M
$-1.3M
Q2 25
$2.1M
$-1.4M
Q1 25
$-129.0K
$-3.5M
Q4 24
$-2.8M
$-1.1M
Q3 24
$1.7M
$-591.6K
Q2 24
$-5.5M
$-803.1K
Q1 24
$2.9M
$-538.3K
Free Cash Flow
GYRE
GYRE
LRHC
LRHC
Q4 25
$-5.8M
Q3 25
$4.0M
Q2 25
$1.8M
Q1 25
$-251.0K
Q4 24
$-2.8M
Q3 24
$1.0M
Q2 24
$-6.9M
Q1 24
$2.7M
FCF Margin
GYRE
GYRE
LRHC
LRHC
Q4 25
-15.5%
Q3 25
13.1%
Q2 25
6.8%
Q1 25
-1.1%
Q4 24
-10.1%
Q3 24
4.1%
Q2 24
-27.5%
Q1 24
9.8%
Capex Intensity
GYRE
GYRE
LRHC
LRHC
Q4 25
0.4%
Q3 25
2.2%
Q2 25
1.0%
Q1 25
0.6%
Q4 24
0.2%
Q3 24
2.7%
Q2 24
5.8%
Q1 24
0.9%
Cash Conversion
GYRE
GYRE
LRHC
LRHC
Q4 25
Q3 25
0.79×
Q2 25
1.32×
-0.02×
Q1 25
-0.03×
Q4 24
-4.85×
Q3 24
0.60×
Q2 24
-1.21×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GYRE
GYRE

Segment breakdown not available.

LRHC
LRHC

Real Estate Residential Brokerage Services$16.8M83%
Transferred Over Time$3.5M17%

Related Comparisons